PainBrake

Drug Profile

PainBrake

Latest Information Update: 08 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Georgetown Translational Pharmaceuticals
  • Class Analgesics; Neuroprotectants
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Neuropathic pain

Most Recent Events

  • 25 Jul 2017 Preclinical trials in Neuropathic pain in USA prior to July 2017 (PO)
  • 25 Jul 2017 Georgetown announces intention to submit NDA to USFDA for Neuropathic pain in 2018
  • 25 Jul 2017 Georgetown Translational Pharmaceuticals intends to file an application for orphan drug designation in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top